Abstract:Objective To investigate the performance of DWI in the prediction of the response of gastrointestinal stromal tumor (GIST) to targeted therapy.Methods Twenty nine consecutive patients with unresectable GIST confirmed by pathology were enrolled in this prospective study.All patients were treated by imatinib mesylate single drug,and had at least one targeted lesion with longest diameter＞ 1 cm.MRI examinations were performed prior to and 2 weeks and 3 months afollowing treatment.The ADC of the whole lesion (ADCentire) and obviously high signal area on DWI (ADCmin) and the longest diameter (LD) on T2WIs were measured.The early percentage changes of the quantitative indicators (％ Δ LD,％ Δ ADCmin and ％ ΔADCentire) were calculated.All patients were divided into good response (GoodR) and poor response (PoorR) groups according to the combined response assessment criteria.The pre-therapy values and early percentage changes (％Δ) of the above quantitative parameters were compared using t test or Mann-Whitney U test.Receiver operating characteristic (ROC) curves were employed to compare the performance of the above quantitative parameters in the discrimination of response groups.Results A total of 82 lesions in 29 patients were included in the study.There were 57 lesions of GoodR and 25 lesions of PoorR.The pre-therapy baseline ADCmin and ADC in GoodR group were both lower than PoorR group [ADCmin:(0.90± 0.27) × 10-3 mm2/s vs.(1.15± 0.29) × 10-3 mm2/s,t=3.673,P＜0.01 ;ADCentire:(1.06 ± 0.26) × 10-3mm2/s vs.(1.31 ± 0.32) × 103mm2/s,t=3.698,P＜0.01].No statistical difference in baseline LD was displayed (P＞0.05).The ％ ΔADC ％ΔADC and ％ΔLD all had statistical difference between GoodR and PoorR groups(％ΔADCmin:48％ vs.3％,Z=-5.310,P＜0.01;％ΔADCentire:45％ vs.2％,Z=-5.768,P＜0.01;％ΔLD:-6％ vs.-1％,Z=-2.752,P＜0.01).Through ROC curves,the AUCs for pre-therapy ADCmin,ADCentire and LD were 0.735,0.721 and 0.503,respectively; and AUCs for ％ΔADCmin,％ΔADCentire and ％ΔLD after two weeks of therapy were 0.859,0.877 and 0.694,respectively,in the differentiation of responses.Using ％ ΔADCmin ≥ 13％ to predict GoodR,the sensitivity was 0.842 and specificity 0.760; Using ％ΔADCentire ≥ 22％ to predict GoodR,the sensitivity was 0.862 and specificity 0.800.Conclusions The percentage changes of the ADC after two weeks of therapy outperform the longest diameter and pre-therapy baseline ADC in the response predictionof GIST to targeted therapy.It is more effective of ADCentire than ADCmin values in the respo nse prediction.

Study of CT Attenuation Value in the Use of Early Evaluation of Imatinib in Treatment of Gastrointestinal Stromal Tumor

To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.

Early Evaluation of Imatinib in Treatment of Gastrointestinal Stromal Tumor Using CT Imaging

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Followed by Sunitinib Compared to Followed by Imatinib-a Multi-Center Cohort Study

Building contrast-enhanced CT-based models for preoperatively predicting malignant potential and Ki67 expression of small intestine gastrointestinal stromal tumors (GISTs)

[Association of CT Image Changes and Prognosis in Gastrointestinal Stromal Tumor after Targeted Therapy].

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

CT Features Combined with RECIST 1.1 Criteria Improve Progression Assessments of Sunitinib-Treated Gastrointestinal Stromal Tumors.

Analysis on the evaluation criteria for therapeutic effect of imatinib in GIST

Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate: Apparent Diffusion Coefficient in the Evaluation of Therapy Response in Patients.

Comprehensive analysis of factors that involve in survival and prognosis in patients with gastrointestinal stromal tumors

Comparative Study on Pre- Diagnosed Computed Tomography Features and Post- Surgery Pathological Risk Grades of the Gastrointestinal Stromal Tumors

The Value of CT in Diagnosing and Following -Up Gastrointestinal Stromal Tumor

Prognosis analysis of patients with intermediate and high risk gastrointestinal stromal tumor after surgery

Prospective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy—Impact on clinical outcome

MR diffusion weighted imaging in the prediction of the response of unresectable gastrointestinal stromal tumor to targeted therapy

New Prognostic Parameters for Very-Low-risk Gastrointestinal Stromal Tumors.

The Therapeutic Response of Gastrointestinal Stromal Tumors to Imatinib Treatment Assessed by Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging with Histopathological Correlation

Imaging Evaluation of Targeted Therapy for Gastrointestinal Stromal Tumor

Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours (Gists)

Value of CT-Based Texture Analysis in Preoperative Prediction of the Grade of Gastrointestinal Stromal Tumors Compared to Conventional CT Imaging